CRDL 6-K notes US$11.4M financing and cash runway into Q3 2027

Rhea-AI Filing Summary

Cardiol Therapeutics (CRDL) filed a Form 6-K furnishing a news release as Exhibit 99.1. The exhibit, dated October 21, 2025, states the company completed a US$11.4 million financing and extended its cash runway into Q3 2027.

This is an informational submission under the Exchange Act for foreign private issuers and directs readers to the attached news release for details.

Insights

Equity capital markets analyst

Neutral filing noting completed US$11.4M financing and runway to Q3 2027.

Cardiol Therapeutics furnished a Form 6-K that includes a news release reporting completion of a US$11.4 million financing and an extended cash runway into Q3 2027. The 6-K itself is administrative, pointing to Exhibit 99.1 for specifics.

While completion of financing typically indicates cash inflow, the excerpt provides no structure, pricing, or dilution details. Without those, the market impact is hard to gauge from this text alone.

Subsequent filings or the full Exhibit 99.1 may outline the financing mechanics and any implications for capitalization and operating plans.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-40712

Cardiol Therapeutics Inc.
(Translation of registrant's name into English)

602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

[   ] Form 20-F     [X] Form 40-F

SUBMITTED HEREWITH

Exhibits

Exhibit		Description
99.1		News Release dated October 21, 2025 - Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CARDIOL THERAPEUTICS INC.
	(Registrant)
Date: October 21, 2025	By:	/s/ Chris Waddick
		Chris Waddick
	Title:	Chief Financial Officer

FAQ

What did Cardiol Therapeutics (CRDL) report in its Form 6-K?

It furnished a news release (Exhibit 99.1) stating completion of a US$11.4 million financing and an extended cash runway into Q3 2027.

How much financing did CRDL complete according to the 6-K exhibit?

The exhibit title states a completed US$11.4 million financing.

What runway guidance did Cardiol Therapeutics provide?

The news release title indicates a cash runway into Q3 2027.

Where can investors find the detailed terms of the financing?

Details are referenced in Exhibit 99.1, the news release dated October 21, 2025.

What form type did CRDL use for this update?

A Form 6-K submitted under the Securities Exchange Act for foreign private issuers.